Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Pick Your #1 game to observe - 2Underestimated Metropolitan Experience Urban communities On the planet
- 3Tanzania president remorseful over internet shutdown on election day
- 4Find the Advantages of Deep rooted Getting the hang of: Extending Information and Self-awareness
- 5Tehran defends ship seizure as a legal action, but tensions continue in the Gulf
- National health ranking puts Georgia near bottom of list. Here's why
- The Most Astonishing Arising Advancements to Watch
- Step by step instructions to Keep up with Ideal Oral Cleanliness at Home
- Picking Your Next SUV: 4 Brands Offering Execution, Solace, and Wellbeing
- Allow Innovative Progressions To have a Massive Effect
- Expert advice for new stargazers: How to begin your amateur astronomy journey
- 5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- 6 Modest and Strong Tire Brands
- Hilary Duff releases 'Mature,' her 1st song in 10 years
